Entera Bio Ltd. (ENTX)
ENTX Stock Price Chart
Explore Entera Bio Ltd. interactive price chart. Choose custom timeframes to analyze ENTX price movements and trends.
ENTX Company Profile
Discover essential business fundamentals and corporate details for Entera Bio Ltd. (ENTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jun 2018
Employees
18.00
Website
https://www.enterabio.comCEO
Miranda J. Toledano
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
ENTX Financial Timeline
Browse a chronological timeline of Entera Bio Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.09.
Earnings released on 8 Aug 2025
EPS came in at -$0.06 surpassing the estimated -$0.11 by +45.45%.
Earnings released on 9 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $42.00K .
Earnings released on 28 Mar 2025
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%, while revenue for the quarter reached $82.00K , beating expectations by +105.00%.
Earnings released on 8 Nov 2024
EPS came in at -$0.08 falling short of the estimated -$0.05 by -60.00%, while revenue for the quarter reached $42.00K , beating expectations by +5.00%.
Earnings released on 9 Aug 2024
EPS came in at -$0.06 matching the estimated -$0.06, while revenue for the quarter reached $57.00K .
Earnings released on 10 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 8 Mar 2024
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $4.48M .
Earnings released on 14 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.
Earnings released on 11 Aug 2023
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $14.00K .
Earnings released on 5 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.12 by +33.33%, while revenue for the quarter reached $13.00K , missing expectations by -87.00%.
Earnings released on 27 Mar 2023
EPS came in at -$0.11 falling short of the estimated -$0.11 by -1.26%, while revenue for the quarter reached $14.00K , missing expectations by -72.00%.
Earnings released on 10 Nov 2022
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%, while revenue for the quarter reached $8.00K , missing expectations by -88.57%.
Earnings released on 11 Aug 2022
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $44.00K , missing expectations by -56.00%.
Earnings released on 12 May 2022
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $68.00K , missing expectations by -61.90%.
Earnings released on 8 Mar 2022
EPS came in at $0.21 surpassing the estimated -$0.11 by +290.91%, while revenue for the quarter reached $165.00K , beating expectations by +29.92%.
Earnings released on 10 Nov 2021
EPS came in at -$0.05 surpassing the estimated -$0.10 by +50.00%, while revenue for the quarter reached $140.00K , missing expectations by -25.93%.
Earnings released on 16 Aug 2021
EPS came in at -$0.19 falling short of the estimated -$0.10 by -90.00%, while revenue for the quarter reached $109.00K , beating expectations by +19.72%.
Earnings released on 20 May 2021
EPS came in at -$0.43 falling short of the estimated -$0.12 by -258.33%, while revenue for the quarter reached $157.00K , missing expectations by -29.82%.
Earnings released on 18 Mar 2021
EPS came in at -$0.11 surpassing the estimated -$0.14 by +21.43%, while revenue for the quarter reached $221.00K .
Earnings released on 19 Nov 2020
EPS came in at -$0.09 surpassing the estimated -$0.20 by +55.00%, while revenue for the quarter reached $50.00K , missing expectations by -28.32%.
ENTX Stock Performance
Access detailed ENTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.